Abstract
Chemotherapy induced myelosuppression (CIM), usually manifested as neutropenia, anemia and/or thrombocytopenia, is a common complication of chemotherapy. Although published literature exists on predicting neutropenia risk based on patients' characteristics among patients with breast, colorectal, lung, lymphoid, or ovarian cancer,1,2 or predicting myelosuppression (neutropenia, anemia and/or thrombocytopenia) among NSCLC patients3-4, there is a paucity of studies examining the risk of myelosuppression among patients with SCLC. The association between patient characteristics and myelosuppression in SCLC is examined in this study.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
